Seneca Biopharma (formerly NeuralStem) is a clinical-stage biopharmaceutical company. The Company's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinsona's Disease. NeuralStem's research has allowed them to produce mature, commercial quantities of neural stem cells that can be transplanted into humans as treatments for currently incurable diseases.
Type | Public | |
Founded | 1996 | |
HQ | Germantown, MD, US | Map |
Website | senecabio.com |
USD | |
---|---|
Revenue (FY, 2020) | 13.5k |
Net income (FY, 2020) | (16.3m) |
EBIT (FY, 2020) | (10.7m) |
Market capitalization (31-Oct-2019) | 4.0m |
Closing stock price (31-Oct-2019) | 1.5 |
Cash (31-Dec-2020) | 10.5m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 390.6k | 407.7k | 110.0k | 18.8k | 10.4k | 16.2k | 260.0k | 260.0k | 15.4k | 13.5k |
General and administrative expense | 5.8m | 256.0k | 5.3m | 9.0m | 6.5m | 7.5m | 5.5m | 4.6m | 4.6m | 8.7m |
R&D expense | 7.4m | 6.1m | 7.1m | 8.1m | 12.6m | 13.2m | 8.1m | 4.0m | 4.1m | 2.0m |
Operating expense total | 13.2m | 6.4m | 12.4m | 17.1m | 19.2m | 20.7m | 13.6m | 8.5m | 8.6m | 10.7m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 103.4k | 156.3k | 78.1k | 170.8k | 102.5k | 2.5k | 2.5k | 4.2k | 5.0k | 5.0k | 2.9k | 2.5k | 2.5k | 2.5k | 2.5k | 2.5k | 2.5k | 2.5k | 2.5k | 2.5k | 252.5k | 2.5k | 2.5k | 7.9k | 2.5k | 6.0k | 2.5k | |
General and administrative expense | 1.5m | 1.1m | 1.2m | 821.4k | 1.3m | 1.2m | 1.3m | 1.7m | 3.5m | 1.5m | 2.0m | 1.4m | 1.7m | 1.8m | 3.2m | 1.4m | 1.3m | 1.3m | 1.6m | 1.2m | 1.2m | 1.3m | 1.2m | 944.6k | 971.8k | 1.3m | 1.3m | 1.5m |
R&D expense | 2.1m | 2.1m | 1.4m | 1.6m | 1.4m | 1.7m | 1.9m | 1.8m | 1.6m | 1.9m | 2.1m | 3.2m | 3.3m | 3.4m | 3.1m | 2.5m | 3.6m | 2.9m | 2.6m | 1.4m | 1.2m | 1.0m | 897.1k | 1.5m | 954.5k | 825.5k | 696.9k | 446.0k |
Operating expense total | 3.6m | 3.3m | 2.6m | 2.4m | 2.7m | 2.9m | 3.2m | 3.6m | 5.1m | 3.4m | 4.0m | 4.6m | 5.0m | 5.2m | 6.2m | 3.8m | 4.9m | 4.2m | 4.2m | 2.6m | 2.4m | 2.3m | 2.1m | 2.5m | 1.9m | 2.1m | 2.0m | 1.9m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 6.1m | 4.2m | 5.1m | 2.5m | 9.9m | 12.7m | 11.2m | 16.4m | 18.3m | 15.2m | 11.9m | 13.6m | 8.6m | 13.1m | 7.6m | 11.1m | 5.7m | 11.7m | 6.4m | 9.1m | 9.7m | 7.1m | 5.7m | 4.0m | 2.3m | 7.3m | 10.0m | 15.8m |
Accounts Receivable | 234.4k | 56.9k | 833.0 | 104.3k | 56.8k | 7.5k | 11.4k | 24.5k | 32.8k | 8.2k | 18.8k | 19.2k | 39.2k | 5.1k | 12.7k | 14.7k | 5.3k | 37.5k | 137.4k | 478.7k | 162.0k | 237.8k | 169.9k | 61.2k | 19.0k | 16.9k | ||
Prepaid Expenses | 300.7k | 653.9k | 404.6k | 234.2k | 289.8k | 220.9k | 156.6k | 344.0k | 319.6k | 196.2k | 409.1k | 388.1k | 904.2k | 1.3m | 1.1m | 705.8k | 946.9k | 477.1k | 239.3k | 548.8k | 347.0k | 343.4k | 545.2k | 295.4k | 256.8k | 605.3k | 414.7k | 390.6k |
Current Assets | 6.4m | 4.8m | 5.8m | 2.8m | 10.2m | 13.5m | 12.0m | 17.3m | 34.1m | 30.8m | 27.7m | 29.2m | 24.7m | 19.6m | 8.7m | 11.8m | 6.7m | 17.2m | 11.7m | 14.7m | 10.2m | 7.9m | 6.5m | 4.5m | 2.7m | 8.0m | 10.5m | 16.2m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | (12.5m) | (10.1m) | (19.8m) | (22.6m) | (20.9m) | (21.1m) | (15.7m) | (4.9m) | (8.4m) | (16.3m) |
Depreciation and Amortization | 187.1k | 211.1k | 244.7k | 348.6k | 345.5k | 337.5k | 289.2k | 185.8k | 143.9k | 92.3k |
Accounts Payable | 888.3k | (644.0k) | (116.7k) | 1.4m | (1.0m) | 879.1k | (1.5m) | (37.0k) | (15.7k) | (105.0k) |
Cash From Operating Activities | (8.1m) | (8.5m) | (10.6m) | (11.7m) | (18.9m) | (15.6m) | (13.4m) | (7.7m) | (7.3m) | (9.0m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.2 x |
Seneca Biopharma has 1.86k Twitter Followers. The number of followers has decreased 1.4% quarter over quarter
When was Seneca Biopharma founded?
Seneca Biopharma was founded in 1996.
Who are Seneca Biopharma key executives?
Seneca Biopharma's key executives are Kenneth C. Carter, Cristina Csimma and Matthew Kalnik.
How many employees does Seneca Biopharma have?
Seneca Biopharma has 5 employees.
What is Seneca Biopharma revenue?
Latest Seneca Biopharma annual revenue is $13.5 k.
What is Seneca Biopharma revenue per employee?
Latest Seneca Biopharma revenue per employee is $2.7 k.
Who are Seneca Biopharma competitors?
Competitors of Seneca Biopharma include InVivo Therapeutics, Pandion Therapeutics and Jnana.
Where is Seneca Biopharma headquarters?
Seneca Biopharma headquarters is located at Goldrenrod Building, 20271 Goldenrod Ln #2024, Germantown.
Where are Seneca Biopharma offices?
Seneca Biopharma has offices in Germantown and Rockville.
How many offices does Seneca Biopharma have?
Seneca Biopharma has 2 offices.
Receive alerts for 300+ data fields across thousands of companies